Amphastar Pharmaceuticals Secures Exclusive Licensing Deal with Anji for Innovative Peptide Therapies in Oncology and Ophthalmology
Reuters
Aug 12
<a href="https://laohu8.com/S/AMPH">Amphastar Pharmaceuticals</a> Secures Exclusive Licensing Deal with Anji for Innovative Peptide Therapies in Oncology and Ophthalmology
Amphastar Pharmaceuticals Inc., a biopharmaceutical company specializing in complex generic and proprietary products, has entered into an exclusive licensing agreement with Nanjing Anji Biotechnology Co., Ltd. This collaboration aims to develop, manufacture, and commercialize three proprietary peptides for oncology and ophthalmology applications in the United States and Canada. The agreement, which aligns with Amphastar's mission to introduce novel and innovative therapies, can be extended for an additional ten years or until the relevant patents expire. Dr. Jack Zhang, Amphastar's CEO, highlighted that this partnership significantly enhances their pipeline with potentially best-in-class assets, reinforcing their commitment to transformative patient therapies. Anji will also receive a non-exclusive license to develop and commercialize the products outside the specified territories.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1059047) on August 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.